Cargando…
Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
Allogeneic natural killer (NK) cells are used for adoptive immunotherapy after stem cell transplantation. In order to overcome technical limitations in NK cell purification and activation, the following study investigates the impact of different variables on NK cell recovery, cytotoxicity, and T-cel...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656406/ https://www.ncbi.nlm.nih.gov/pubmed/23730623 http://dx.doi.org/10.3389/fonc.2013.00118 |
_version_ | 1782270017213038592 |
---|---|
author | Koehl, Ulrike Brehm, Claudia Huenecke, Sabine Zimmermann, Stefanie-Yvonne Kloess, Stephan Bremm, Melanie Ullrich, Evelyn Soerensen, Jan Quaiser, Andrea Erben, Stephanie Wunram, Claudia Gardlowski, Tanja Auth, Eileen Tonn, Torsten Seidl, Christian Meyer-Monard, Sandrine Stern, Martin Passweg, Jakob Klingebiel, Thomas Bader, Peter Schwabe, Dirk Esser, Ruth |
author_facet | Koehl, Ulrike Brehm, Claudia Huenecke, Sabine Zimmermann, Stefanie-Yvonne Kloess, Stephan Bremm, Melanie Ullrich, Evelyn Soerensen, Jan Quaiser, Andrea Erben, Stephanie Wunram, Claudia Gardlowski, Tanja Auth, Eileen Tonn, Torsten Seidl, Christian Meyer-Monard, Sandrine Stern, Martin Passweg, Jakob Klingebiel, Thomas Bader, Peter Schwabe, Dirk Esser, Ruth |
author_sort | Koehl, Ulrike |
collection | PubMed |
description | Allogeneic natural killer (NK) cells are used for adoptive immunotherapy after stem cell transplantation. In order to overcome technical limitations in NK cell purification and activation, the following study investigates the impact of different variables on NK cell recovery, cytotoxicity, and T-cell depletion during good manufacturing practice (GMP)-grade NK cell selection. Forty NK cell products were derived from 54 unstimulated donor leukaphereses using immunomagnetic CD3 T-cell depletion, followed by a CD56 cell enrichment step. For T-cell depletion, either the depletion 2.1 program in single or double procedure (D2.1(1depl), n = 18; D2.1(2depl), n = 13) or the faster depletion 3.1 (D3.1, n = 9) was used on the CliniMACS instrument. Seventeen purified NK cell products were activated in vitro by IL-2 for 12 days. The whole process resulted in a median number of 7.59 × 10(8) CD56(+)CD3(−) cells with both purity and viability of 94%, respectively. The T-cell depletion was significantly better using D2.1(1depl/2depl) compared to D3.1 (log 4.6/log 4.9 vs. log 3.7; p < 0.01) and double procedure in two stages led always to residual T cells below 0.1%. In contrast D3.1 was superior to D2.1(1depl/2depl) with regard to recovery of CD56(+)CD3(−) NK cells (68% vs. 41%/38%). Concomitant monocytes and especially IL-2 activation led to increased NK cell activity against malignant target cells compared to unstimulated NK cells, which correlated with both up-regulation of natural cytotoxicity receptors and intracellular signaling. Overall, wide variations in the NK cell expansion rate and the distribution of NK cell subpopulations were found. In conclusion, our results indicate that GMP-grade purification of NK cells might be improved by a sequential processing of T-cell depletion program D2.1 and D3.1. In addition NK cell expansion protocols need to be further optimized. |
format | Online Article Text |
id | pubmed-3656406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-36564062013-05-31 Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol Koehl, Ulrike Brehm, Claudia Huenecke, Sabine Zimmermann, Stefanie-Yvonne Kloess, Stephan Bremm, Melanie Ullrich, Evelyn Soerensen, Jan Quaiser, Andrea Erben, Stephanie Wunram, Claudia Gardlowski, Tanja Auth, Eileen Tonn, Torsten Seidl, Christian Meyer-Monard, Sandrine Stern, Martin Passweg, Jakob Klingebiel, Thomas Bader, Peter Schwabe, Dirk Esser, Ruth Front Oncol Oncology Allogeneic natural killer (NK) cells are used for adoptive immunotherapy after stem cell transplantation. In order to overcome technical limitations in NK cell purification and activation, the following study investigates the impact of different variables on NK cell recovery, cytotoxicity, and T-cell depletion during good manufacturing practice (GMP)-grade NK cell selection. Forty NK cell products were derived from 54 unstimulated donor leukaphereses using immunomagnetic CD3 T-cell depletion, followed by a CD56 cell enrichment step. For T-cell depletion, either the depletion 2.1 program in single or double procedure (D2.1(1depl), n = 18; D2.1(2depl), n = 13) or the faster depletion 3.1 (D3.1, n = 9) was used on the CliniMACS instrument. Seventeen purified NK cell products were activated in vitro by IL-2 for 12 days. The whole process resulted in a median number of 7.59 × 10(8) CD56(+)CD3(−) cells with both purity and viability of 94%, respectively. The T-cell depletion was significantly better using D2.1(1depl/2depl) compared to D3.1 (log 4.6/log 4.9 vs. log 3.7; p < 0.01) and double procedure in two stages led always to residual T cells below 0.1%. In contrast D3.1 was superior to D2.1(1depl/2depl) with regard to recovery of CD56(+)CD3(−) NK cells (68% vs. 41%/38%). Concomitant monocytes and especially IL-2 activation led to increased NK cell activity against malignant target cells compared to unstimulated NK cells, which correlated with both up-regulation of natural cytotoxicity receptors and intracellular signaling. Overall, wide variations in the NK cell expansion rate and the distribution of NK cell subpopulations were found. In conclusion, our results indicate that GMP-grade purification of NK cells might be improved by a sequential processing of T-cell depletion program D2.1 and D3.1. In addition NK cell expansion protocols need to be further optimized. Frontiers Media S.A. 2013-05-17 /pmc/articles/PMC3656406/ /pubmed/23730623 http://dx.doi.org/10.3389/fonc.2013.00118 Text en Copyright © 2013 Koehl, Brehm, Huenecke, Zimmermann, Kloess, Bremm, Ullrich, Soerensen, Quaiser, Erben, Wunram, Gardlowski, Auth, Tonn, Seidl, Meyer-Monard, Stern, Passweg, Klingebiel, Bader, Schwabe and Esser. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Oncology Koehl, Ulrike Brehm, Claudia Huenecke, Sabine Zimmermann, Stefanie-Yvonne Kloess, Stephan Bremm, Melanie Ullrich, Evelyn Soerensen, Jan Quaiser, Andrea Erben, Stephanie Wunram, Claudia Gardlowski, Tanja Auth, Eileen Tonn, Torsten Seidl, Christian Meyer-Monard, Sandrine Stern, Martin Passweg, Jakob Klingebiel, Thomas Bader, Peter Schwabe, Dirk Esser, Ruth Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title | Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title_full | Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title_fullStr | Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title_full_unstemmed | Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title_short | Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol |
title_sort | clinical grade purification and expansion of nk cell products for an optimized manufacturing protocol |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3656406/ https://www.ncbi.nlm.nih.gov/pubmed/23730623 http://dx.doi.org/10.3389/fonc.2013.00118 |
work_keys_str_mv | AT koehlulrike clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT brehmclaudia clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT hueneckesabine clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT zimmermannstefanieyvonne clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT kloessstephan clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT bremmmelanie clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT ullrichevelyn clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT soerensenjan clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT quaiserandrea clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT erbenstephanie clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT wunramclaudia clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT gardlowskitanja clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT autheileen clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT tonntorsten clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT seidlchristian clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT meyermonardsandrine clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT sternmartin clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT passwegjakob clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT klingebielthomas clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT baderpeter clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT schwabedirk clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol AT esserruth clinicalgradepurificationandexpansionofnkcellproductsforanoptimizedmanufacturingprotocol |